摘要
目的:观察四君子汤加减治疗慢性胃炎的临床疗效和不良反应发生情况。方法:选取2012年1月至2016年12月开封市中医院收治的慢性胃炎患者100例,按照随机数字表法分为观察和对照组,每组50例。2组患者均采用质子泵抑制剂治疗,观察组此基础上加入四君子汤,治疗后比较2组疗效、症状积分、不良反应、血浆胃动素(MTL)和生长抑素(SS)水平。结果:治疗后观察组和对照组有效率分别为90. 00%,70. 00%,差异有统计学意义(P <0. 05);治疗前,2组患者症状积分差异无统计学意义(P> 0. 05),治疗后,观察组的症状积分低于对照组,差异有统计学意义(P <0. 05);不良反应观察组有4例,占8. 0%,对照组有12例,占22. 5%,差异有统计学意义(P <0. 05);治疗前,2组患者血浆MTL和SS水平差异无统计学意义(P> 0. 05),治疗4周后,2组患者血浆MTL水平均降低,SS升高,但观察组的变化比对照组大,P <0. 05。结论:四君子汤加减治疗慢性胃炎效果好且安全性高。
Objective To observe the clinical efficacy and adverse reaction of Sijunzi Decoction in the treatment of chronic gastritis. Methods: From January 2012 to December 2016, 100 patients with chronic gastritis in our hospital were enrolled in this study. They were divided into observation group and control group with random number table method, with 50 cases in each group. 2 groups of patients had basic treatment, which was PPI, and the observation group was added Sijunzi decoction. After treatment, efficacy, symptom score, side effects, plasma MTL and SS concentration of two groups were compared. Results: 1)The effective rates of the observation group and the control group were 89.23%, 72.14% ( P 〈0.05), and the difference was statistically significant. The observation group was more effective than the control group; 2)The symptom score in the two groups were not comparable before treatment. After treatment, the observation group was lower than the control group ( P 〈0.05). 3)During the treatment progress, both groups showed adverse reactions. 4 cases in observation group, accounted for 8/%. 12 cases in control group, accounted for 22.5% ( P 〈0.05). 4)There was no significant difference in plasma MTL and SS concentration between the two groups before treatment ( P 〉0.05). After 4 weeks of treatment, plasma MTL concentration decreased and SS increased, but the degree of change in the observation group was larger than that in the control group ( P 〈0.05). Conclusion: Sijunzi Decoction is effective and safe in the treatment of chronic gastritis.
作者
杨淑娟
董世旭
周永志
徐敬江
付凯
王红霞
Yang Shujuan;Dong Shixu;Zhou Yongzhi;Xu Jingjiang;Fu Kai;Wang Hognxia(Department of Liver,Gallbladder,Spleen and Stomach Disease,Kaifeng City Hospital of Traditional Chinese Medicine,Kaifeng 475000,China;Department of Diabetes and Nephropathy,Kaifeng City Hospitalof Traditional Chinese Medicine,Kaifeng 475000,China)
出处
《世界中医药》
CAS
2018年第10期2480-2483,共4页
World Chinese Medicine
基金
河南省卫生厅卫生政策研究课题计划(YWZY201406)